Search Results

The Lupus Research Alliance announced the recipients of the 2024 Lupus Insight Prize to Marko Radic, Ph.D., The University of Tennessee Health Science Center, and Georg Schett, M.D., Friedrich-Alexander-Universität Erlangen-Nürnberg, for their groundbreaking discoveries in utilizing CAR T cell therapy to potentially revolutionize lupus treatment.

The Lupus Research Alliance is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award, whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus.

The Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics today announced the launch of the Lupus Landmark Study, a groundbreaking observational research study to accelerate the development of personalized treatments for people living with lupus.

The Lupus Foundation of America is pleased to announce six recipients of the 2024 Gina M. Finzi Memorial Student Summer Fellowship Program.

The Lupus Research Alliance (LRA), founder and administrator of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), announced today at the Consortium’s first anniversary meeting an expanded partnership with the U.S. Food and Drug Administration (FDA) with the inclusion of the Center for Biologics Evaluation and Research (CBER).

The Lupus Research Alliance is pleased to announce results from more than 30 studies supported by the LRA and its clinical research affiliate Lupus Therapeutics will be presented at ACR Convergence 2023, the annual meeting of the American College of Rheumatology.

Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics to support the development of the patient registry component of the Lupus Nexus, which aims to advance and accelerate lupus research and drug discovery through information exchange capabilities.

In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis versus placebo, positioning Roche’s therapeutic antibody for expansion into the indication.

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a partnership with AbbVie Inc. for the Phase 3 clinical program of upadacitinib (RINVOQ ® ) in individuals living with systemic lupus erythematosus (SLE).

The Lupus Research Alliance (LRA) today announced the recipients of the newest Lupus Innovation Award (LIA) grants.